Q1 EPS Forecast for Lexeo Therapeutics Lifted by Analyst

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Stock analysts at HC Wainwright upped their Q1 2025 earnings estimates for shares of Lexeo Therapeutics in a research report issued on Wednesday, March 26th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.78) per share for the quarter, up from their previous forecast of ($0.93). HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. HC Wainwright also issued estimates for Lexeo Therapeutics’ Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.66) EPS and FY2025 earnings at ($2.95) EPS.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its earnings results on Monday, March 24th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09.

A number of other analysts have also recently commented on the company. Leerink Partners reduced their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday. Chardan Capital restated a “buy” rating and set a $25.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday. Finally, Royal Bank of Canada lowered their price target on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $22.80.

Lexeo Therapeutics Price Performance

Shares of Lexeo Therapeutics stock opened at $4.11 on Friday. The stock has a market cap of $135.90 million, a P/E ratio of -1.30 and a beta of 3.85. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. The stock’s fifty day moving average is $4.07 and its 200 day moving average is $6.63. Lexeo Therapeutics has a one year low of $2.32 and a one year high of $19.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LXEO. Wellington Management Group LLP grew its stake in shares of Lexeo Therapeutics by 48.3% in the 4th quarter. Wellington Management Group LLP now owns 76,981 shares of the company’s stock worth $507,000 after buying an additional 25,089 shares in the last quarter. Woodline Partners LP lifted its holdings in shares of Lexeo Therapeutics by 0.8% in the 4th quarter. Woodline Partners LP now owns 858,691 shares of the company’s stock worth $5,650,000 after acquiring an additional 6,730 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Lexeo Therapeutics by 41.2% during the 4th quarter. Vestal Point Capital LP now owns 1,200,000 shares of the company’s stock worth $7,896,000 after purchasing an additional 350,000 shares during the period. Point72 Asset Management L.P. grew its holdings in Lexeo Therapeutics by 102.5% during the 4th quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company’s stock valued at $4,937,000 after purchasing an additional 379,828 shares during the last quarter. Finally, Millennium Management LLC raised its position in Lexeo Therapeutics by 282.5% in the 4th quarter. Millennium Management LLC now owns 141,951 shares of the company’s stock worth $934,000 after purchasing an additional 104,837 shares during the period. 60.67% of the stock is currently owned by institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.